Press

Acarix two largest shareholders transfer subscription rights free of charge –extends the subscription period

 

he shareholders Sunstone LSV Fund II K / S and SEED Capital DK II K / S have transferred all
of the subscription rights they were entitled to in the Rights Issue, amounting to a total of 47,490,810
rights, corresponding to 18.37 percent of the Rights Issue. The subscription rights have been
transferred to a number of qualified investors who have agreed to subscribe for shares using the
subscription rights, corresponding to a subscription value of SEK 10.3 million in the Rights issue.

Acarix_PR_transfer_of_rights

Acarix_PM_överlåtelse_teckningsrätter

 

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.